Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?
- 1 May 2005
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 24 (3), 622-630
- https://doi.org/10.1377/hlthaff.24.3.622
Abstract
During the past fifty years, the number of pharmaceutical companies making vaccines has decreased dramatically, and those that still make vaccines have reduced resources to make new ones. Pharmaceutical companies are gradually abandoning vaccines because the research, development, testing, and manufacture of vaccines are expensive and because the market to sell vaccines is much smaller than the market for other drug products. Congressional action could assure both a steady supply of existing vaccines and the promise of vaccines for the future.Keywords
This publication has 10 references indexed in Scilit:
- Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal AssociationPediatrics, 2004
- Strengthening the Supply of Routinely Recommended Vaccines in the United StatesJAMA, 2003
- U.S. Vaccine Supply Falls Seriously ShortScience, 2002
- Intussusception among Infants Given an Oral Rotavirus VaccineNew England Journal of Medicine, 2001
- A Vaccine Consisting of RecombinantBorrelia burgdorferiOuter-Surface Protein A to Prevent Lyme DiseaseNew England Journal of Medicine, 1998
- Changing Rules in Tort Law and the Market for Childhood VaccinesThe Journal of Law and Economics, 1994
- Immunization of Pregnant Women with a Polysaccharide Vaccine of Group B StreptococcusNew England Journal of Medicine, 1988
- Eradication of Poliomyelitis in the United StatesClinical Infectious Diseases, 1982
- Neurological complications of pertussis inoculationArchives of Disease in Childhood, 1974
- STUDIES IN HUMAN SUBJECTS ON ACTIVE IMMUNIZATION AGAINST POLIOMYELITISJAMA, 1953